| Drug Type T cell engagers (TCE) | 
| Synonyms 5T4-CD3 T cell engager (Sutro Biopharma) | 
| Target | 
| Action inhibitors, stimulants | 
| Mechanism 5T4 inhibitors(Trophoblast glycoprotein inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Solid tumor | Preclinical | United States  | 29 Mar 2022 | 






